CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 158 enrolled
Drug / intervention
XEN-45 Gel Stent +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03654885
NCT03654885Phase 4Completed
CompareCT.gov

XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)

Allergan·interventional·Posted Aug 31, 2018·Updated Jul 21, 2022

In Brief

A Phase 4 clinical trial evaluating XEN-45 Gel Stent and Trabeculectomy for Glaucoma. Completed, enrolled 158 participants across 35 sites.

Detailed Summary

The purpose of this study is to compare the safety and efficacy of XEN-45 to trabeculectomy in participants with open angle glaucoma refractory to topical medical therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedAug 31, 2018
Enrollment StartOct 1, 2018
Primary CompletionMay 13, 2021
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 7.8 years ago

Interventions

XEN-45 Gel Stentdevice

XEN-45 gel stent device implant

Trabeculectomyprocedure

Trabeculectomy surgery